More than 50 years of landmark results
Since 1967, Lowey Dannenberg has represented investors and major corporations in complex litigation, recovering billions of dollars on their behalf.Solutions for Complex Cases
Professional Recommendations
Recent Cases

Roche v. Aetna, Inc.
Healthcare, Notable
Lowey Dannenberg is defending Aetna in a class action related to state anti-subrogation laws. Minerley v. Aetna Inc., et al., 13-cv-1337 (D.N.J.). Lowey Dannenberg has defended and won dismissal of several similar class action lawsuits against health insurance clients: Wurtz v. Rawlings Co., LLC, 2016 WL 7174674 (E.D.N.Y. Nov. 17, 2016); Meek-Horton v. Trover, et al., 910 F.Supp. 2d 690 (S.D.N.Y. 2013); Potts v. Rawlings Co. LLC, 897 F.Supp. 2d 185 (S.D.N.Y. 2012).

Federated Investment Management Company, et al., v. Republic of Argentina
Antitrust
Lowey obtained emergency injunctive relief on behalf of Federated Investors, one of the largest investment firms in the country with over $363 billion in assets under management, preventing the Government of Argentina from canceling outstanding bonds with a face value of more than $500 million, which had been erroneously tendered by those bondholders. Federated Investment Management Company, et al., v. Republic of Argentina, et al., 10 Civ. 4324 (S.D.N.Y. 2010) (Griesa, J.).

Juniper Networks
Notable
Lowey Dannenberg served as lead counsel, representing the New York City Pension Funds and related class members, alleging that Juniper Networks, Inc. fraudulently concealed the backdating of millions of stock options, resulting in a $900 million financial restatement.
News
Lowey Dannenberg Wins Class Certification in Ranbaxy Generic-Delay Case
On May 14, 2021, Judge Nathaniel M. Gorton of the U.S. District Court for the District of Massachusetts granted the End-Payor Plaintiffs’ (“EPPs’”) class certification motion. The EPPs are third party payors paying some or all of the purchase price for prescription…
Blog
Pharma Industry Takes Advantage of COVID Epidemic to Mislead Investors
Recently, several major players in the pharmaceutical industry have faced severe shareholder scrutiny for misleading the public regarding their roles in the production of COVID-19 vaccines. The company to most recently fall in the limelight is Emergent Biosolutions (“Emergent”). Emergent had…





